Baiyunshan announced that the subsidiary Baiyunshan Hanfang received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The drug names are LBZ-18 and LBZ-18 oral milk, and the registered classification is traditional Chinese medicine class 1.2. As of the announcement date, Baiyunshan Hanfang has invested about RMB 29.36 million in R&D expenses (unaudited) in the above drug research and development projects. Currently, there are no drugs to treat cancer-induced fatigue on the market at home or abroad, and there is no sales data.